Şahin U - Search Results

1

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.

Frenck RW Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, Perez JL, Walter EB, Senders S, Bailey R, Swanson KA, Ma H, Xu X, Koury K, Kalina WV, Cooper D, Jennings T, Brandon DM, Thomas SJ, Türeci Ö, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Frenck RW Jr, et al. Among authors: sahin u. N Engl J Med. 2021 Jul 15;385(3):239-250. doi: 10.1056/NEJMoa2107456. Epub 2021 May 27. N Engl J Med. 2021. PMID: 34043894 Free PMC article. Clinical Trial.

2

Serological analysis of human tumor antigens: molecular definition and implications.

Türeci O, Sahin U, Pfreundschuh M. Türeci O, et al. Among authors: sahin u. Mol Med Today. 1997 Aug;3(8):342-9. doi: 10.1016/s1357-4310(97)01081-2. Mol Med Today. 1997. PMID: 9269687 Review.

3

Serological identification of human tumor antigens.

Sahin U, Türeci O, Pfreundschuh M. Sahin U, et al. Curr Opin Immunol. 1997 Oct;9(5):709-16. doi: 10.1016/s0952-7915(97)80053-2. Curr Opin Immunol. 1997. PMID: 9368781 Review.

4

SeroGRID: an improved method for the rapid selection of antigens with disease related immunogenicity.

Krause P, Türeci O, Micke P, Buhl R, Huber C, Sahin U. Krause P, et al. Among authors: sahin u. J Immunol Methods. 2003 Dec;283(1-2):261-7. doi: 10.1016/j.jim.2003.09.014. J Immunol Methods. 2003. PMID: 14659917

5

Identification of tumor-associated autoantigens with SEREX.

Türeci O, Usener D, Schneider S, Sahin U. Türeci O, et al. Among authors: sahin u. Methods Mol Med. 2005;109:137-54. doi: 10.1385/1-59259-862-5:137. Methods Mol Med. 2005. PMID: 15585919

6

The human X chromosome is enriched for germline genes expressed in premeiotic germ cells of both sexes.

Koslowski M, Sahin U, Huber C, Türeci O. Koslowski M, et al. Among authors: sahin u. Hum Mol Genet. 2006 Aug 1;15(15):2392-9. doi: 10.1093/hmg/ddl163. Epub 2006 Jun 29. Hum Mol Genet. 2006. PMID: 16809397

7

MS4A12 is a colon-selective store-operated calcium channel promoting malignant cell processes.

Koslowski M, Sahin U, Dhaene K, Huber C, Türeci O. Koslowski M, et al. Among authors: sahin u. Cancer Res. 2008 May 1;68(9):3458-66. doi: 10.1158/0008-5472.CAN-07-5768. Cancer Res. 2008. PMID: 18451174

8

Selective activation of tumor growth-promoting Ca2+ channel MS4A12 in colon cancer by caudal type homeobox transcription factor CDX2.

Koslowski M, Türeci O, Huber C, Sahin U. Koslowski M, et al. Among authors: sahin u. Mol Cancer. 2009 Sep 25;8:77. doi: 10.1186/1476-4598-8-77. Mol Cancer. 2009. PMID: 19781065 Free PMC article.

9

Tumor vaccination using messenger RNA: prospects of a future therapy.

Kreiter S, Diken M, Selmi A, Türeci Ö, Sahin U. Kreiter S, et al. Among authors: sahin u. Curr Opin Immunol. 2011 Jun;23(3):399-406. doi: 10.1016/j.coi.2011.03.007. Epub 2011 Apr 13. Curr Opin Immunol. 2011. PMID: 21497074 Review.

10

Targeting the tumor mutanome for personalized vaccination therapy.

Kreiter S, Castle JC, Türeci O, Sahin U. Kreiter S, et al. Among authors: sahin u. Oncoimmunology. 2012 Aug 1;1(5):768-769. doi: 10.4161/onci.19727. Oncoimmunology. 2012. PMID: 22934277 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

487 results

Search Page